04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
20:02 , Nov 2, 2018 |  BC Week In Review  |  Company News

Sanofi deal will bank roll Denali's indication expansion

Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most...
15:33 , Nov 1, 2018 |  BC Extra  |  Company News

Sanofi deal will bank roll Denali's indication expansion

Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most...
22:53 , Jul 20, 2018 |  BC Extra  |  Preclinical News

RIPK1 mutations in humans linked to IBD, arthritis

A study published in...
16:58 , Mar 22, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting RIPK1 or MCU could help treat colorectal cancer. In patient samples, tumor levels of RIPK1 and MCU were higher than in adjacent normal...
20:02 , Aug 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Necroptosis strikes again

Adding to the list of necroptosis-related pathologies, a group from Arizona State University has shown the cell death pathway is activated in Alzheimer’s disease. The data, published last month in...